Sign In
Buy MESO
$14.52
+0 (+0%)
At Close: Jun 03, 2026
Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
07:44pm, Monday, 28'th Apr 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Coble
Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives
09:20pm, Wednesday, 16'th Apr 2025
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has continued to expand
Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs
06:58pm, Thursday, 03'rd Apr 2025
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the status of its p
Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure
07:15pm, Wednesday, 02'nd Apr 2025
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet w
First Three Children to Commence Treatment With Ryoncil®
07:39pm, Sunday, 30'th Mar 2025
United States Centers for Medicare and Medicaid Services (CMS) Mandates Ryoncil® Coverage United States Centers for Medicare and Medicaid Services (CMS) Mandates Ryoncil® Coverage
Ryoncil® is Now Available for Purchase in the United States
08:19pm, Wednesday, 26'th Mar 2025
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil® (remeste
Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States
07:42pm, Thursday, 13'th Mar 2025
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that pricing informatio
Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
07:30am, Wednesday, 12'th Mar 2025
NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that Chief Executive Si
Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript
11:38am, Friday, 28'th Feb 2025
Mesoblast Limited (NASDAQ:MESO ) Q2 2025 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Silviu Itescu - Chief Executive Officer & Managing Director Andrew Chaponnel - Inter
Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter
05:30pm, Wednesday, 26'th Feb 2025
Financial Results and Operational Update for Half-Year Ended December 31, 2024 Financial Results and Operational Update for Half-Year Ended December 31, 2024
Mesoblast Limited (MESO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
11:01am, Wednesday, 26'th Feb 2025
Mesoblast Limited (MESO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could
Mesoblast Financial Results and Corporate Update Webcast
06:13pm, Tuesday, 25'th Feb 2025
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation
Dr. Gregory George MD PhD Joins Mesoblast Board
06:33pm, Sunday, 23'rd Feb 2025
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr
Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
06:37pm, Thursday, 13'th Feb 2025
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its recently appr
Ryoncil® Commercial Launch Update and Product Pipeline
07:11pm, Thursday, 30'th Jan 2025
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the progress
